Previous 10 | Next 10 |
Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline €129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026 LEID...
2023-08-01 11:43:52 ET More on ProQR ProQR: Too Many Failures For Its RNA Technology ProQR adds 75% as Cantor upgrades on expanded deal with Eli Lilly Eli Lilly sends ProQR 35% higher after expanding RNA editing deal AstraZeneca – LogicBio deal indicat...
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer&...
2023-07-09 06:53:51 ET Summary PRQR, last year, failed a pivotal trial. This is the third time it has failed trials after showing early signs of efficacy. While they are making an effort, I see little future here. In June 2021, I covered ProQR ( PRQR ) when i...
2023-07-09 03:09:09 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: The Week Ahead
2023-07-07 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced a present...
2023-05-16 07:18:09 ET ProQR press release ( NASDAQ: PRQR ): Q1 GAAP EPS of -€0.11. Revenue of €0.66M (-41.6% Y/Y). For further details see: ProQR GAAP EPS of -€0.11, revenue of €0.66M
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues across multiple therapeutic areas Strength of intellectual property es...
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today announced...
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27 th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data Martin Maier, PhD nominated to Board with Annual General Meeting scheduled f...
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 pr...
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the An...